more blog

More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.

In the TOP-1 trial, omitting RT and endocrine therapy after breast-conserving surgery yielded a 14.8% 5-year local recurrence risk in women aged 70 and older.

A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.

Data from the phase 3 HARMONi-GI1 trial support first-line ivonescimab plus chemotherapy as a new standard of care in advanced biliary tract cancer.

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.

Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma in CLARITY-Gastric01.

Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.

Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.